Ash, a buyout with this pps would be an unmitigated disaster. The decline of profit can be blamed on Fusilev, but not entirely. Expenditures to enable the FDA to approve our current NDAs is vital for future growth. Personally, I consider this akin to being house-poor. or growing pains. In order to become far more than it is now. That hurts now, but long term, it's the only way to grow..